Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.
Charles M. Rudin, MD, PhD
Professor
Research Focus
Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.Education
MD, PhD, University of Chicago Pritzker School of MedicineLab Members
John Poirier
Lab co-Director
Viola Allaj
Senior Research Technician
Metamia Ciampricotti
Postdoctoral Researcher
Christopher Hulton
Graduate Student
Corrin Pimentel
Graduate Student
Nisarg Shah
Research Assistant/Lab Manager
Alba Chacon
Postdoctoral Researcher
Andrew Chow
Medical Oncology Fellow
Karen Chu
Graduate Student
Emily Costa
Graduate Student
Michael Offin
Medical Oncology Fellow
Álvaro Quintanal Villalonga
Research Fellow
Publications
- Miles LA, Burga LN, Gardner EE, Bostina M, Poirier JT, Rudin CM. Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley Virus. J Clin Invest 127:2957-67, 2017.
- Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, Sage J, Campbell JE, Ribich S, Rekhtman N, Dowlati A, Massion PP, Rudin CM, Poirier JT. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis. Cancer Cell 31: 286-99, 2017.
